Late-Breaking abstract submissions will be considered for:
1. Phase III and Phase II Clinical Trials
- Practice-changing data for which no preliminary results were available at the regular abstract submission deadline
- Studies with potential to immediately impact clinical practice in breast cancer care
2. High-Impact Original Research
- Novel research findings with significant implications for clinical practice
- Studies that substantially advance understanding of breast cancer biology or disease processes
- Research with immediate relevance to patient care and treatment decision-making